Search

Your search keyword '"Loong, Herbert H."' showing total 311 results
Start Over Author "Loong, Herbert H."
311 results on '"Loong, Herbert H."'

1. International Multicenter Retrospective Study From the Ultra-rare Sarcoma Working Group on Low-grade Fibromyxoid Sarcoma, Sclerosing Epithelioid Fibrosarcoma, and Hybrid Forms: Outcome of Primary Localized Disease

Author

Giani, Claudia, Salawu, Abdulazeez, Ljevar, Silva, Denu, Ryan A., Napolitano, Andrea, Palmerini, Emanuela, Connolly, Elizabeth A., Ogura, Koichi, Wong, Daniel D., Scanferla, Roberto, Rosenbaum, Evan, Bajpai, Jyoti, Li, Zola Chia-Chen, Bae, Susie, D’Ambrosio, Lorenzo, Bialick, Steve, Wagner, Andrew J., Lee, Alexander T.J., Koseła-Paterczyk, Hanna, Baldi, Giacomo G., Brunello, Antonella, Lee, Yeh Chen, Loong, Herbert H., Boikos, Sosipatros, Campos, Fernando, Cicala, Carlo M., Maki, Robert G., Hindi, Nadia, Figura, Costanza, Almohsen, Shahd S., Patel, Sheyaskumar, Jones, Robin L., Ibrahim, Toni, Karim, Rooshdiya, Kawai, Akira, Carey-Smith, Richard, Boyle, Richard, Taverna, Silvia M., Lazar, Alexander J., Demicco, Elizabeth G., Bovee, Judith V.M.G., Dei Tos, Angelo P., Fletcher, Christopher, Baumhoer, Daniel, Sbaraglia, Marta, Schaefer, Inga-Marie, Miceli, Rosalba, Gronchi, Alessandro, and Stacchiotti, Silvia

Published
2025
Full Text
View/download PDF

7. Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 TrialIntracranial Efficacy of Selpercatinib in RET Fusion+ NSCLC

Author

Subbiah, Vivek, Gainor, Justin F, Oxnard, Geoffrey R, Tan, Daniel SW, Owen, Dwight H, Cho, Byoung Chul, Loong, Herbert H, McCoach, Caroline E, Weiss, Jared, Kim, Yu Jung, Bazhenova, Lyudmila, Park, Keunchil, Daga, Haruko, Besse, Benjamin, Gautschi, Oliver, Rolfo, Christian, Zhu, Edward Y, Kherani, Jennifer F, Huang, Xin, Kang, Suhyun, and Drilon, Alexander

Subjects
Lung Cancer, Brain Disorders, Cancer, Clinical Trials and Supportive Activities, Lung, Clinical Research, Neurosciences, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Aged, 80 and over, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Proto-Oncogene Proteins c-ret, Pyrazoles, Pyridines, Treatment Outcome, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeWe report the intracranial efficacy of selpercatinib, a highly potent and selective RET inhibitor, approved in the United States for RET fusion-positive non-small cell lung cancers (NSCLC).Patients and methodsIn the global phase 1/2 LIBRETTO-001 trial (NCT03157128) in advanced RET-altered solid tumors, selpercatinib was dosed orally (160 mg twice every day) in 28-day cycles. Patients with baseline intracranial metastases had MRI/CT scans every 8 weeks for 1 year (12 weeks thereafter). In this pre-planned analysis of patients with RET fusion-positive NSCLC with baseline intracranial metastases, the primary endpoint was independently assessed intracranial objective response rate (ORR) per RECIST 1.1. Secondary endpoints included intracranial disease control rate, intracranial duration of response, and intracranial progression-free survival (PFS) independently reviewed.ResultsEighty patients with NSCLC had brain metastases at baseline. Patients were heavily pretreated (median = 2 systemic therapies, range = 0-10); 56% of patients received ≥1 course of intracranial radiation (14% whole brain radiotherapy, 45% stereotactic radiosurgery). Among 22 patients with measurable intracranial disease at baseline, intracranial ORR was 82% [95% confidence interval (CI), 60-95], including 23% with complete responses. Among all intracranial responders (measurable and nonmeasurable, n = 38), median duration of intracranial response was not reached (95% CI, 9.3-NE) at a median duration of follow-up of 9.5 months (IQR = 5.7, 12.0). At 12 months, 55% of intracranial responses were ongoing. In all 80 patients, median intracranial PFS was 13.7 months (95% CI, 10.9-NE) at a median duration of follow-up of 11.0 months (IQR = 7.4, 16.5). No new safety signals were revealed in patients with brain metastases compared with the full NSCLC trial population.ConclusionsSelpercatinib has robust and durable intracranial efficacy in patients with RET fusion-positive NSCLC.

Published
2021

9. The impact of the multi-disciplinary molecular tumour board and integrative next generation sequencing on clinical outcomes in advanced solid tumours

Author

El Helali, Aya, Lam, Tai-Chung, Ko, Elaine Yee-Ling, Shih, David J.H., Chan, Chun Kau, Wong, Charlene H.L., Wong, Jason W.H., Cheung, Lydia W.T., Lau, Johnny K.S., Liu, Anthony P.Y., Chan, Ann S.Y., Loong, Herbert H., Lam, Stephen Tak Sum, Chan, Godfrey Chi-Fung, Lee, Victor H.F., Yuen, Kwok Keung, Ng, Wai-Tong, Lee, Anne W.M., and Ma, Edmond S.K.

Published
2023
Full Text
View/download PDF

10. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

Author

Doebele, Robert C, Drilon, Alexander, Paz-Ares, Luis, Siena, Salvatore, Shaw, Alice T, Farago, Anna F, Blakely, Collin M, Seto, Takashi, Cho, Byung Chul, Tosi, Diego, Besse, Benjamin, Chawla, Sant P, Bazhenova, Lyudmila, Krauss, John C, Chae, Young Kwang, Barve, Minal, Garrido-Laguna, Ignacio, Liu, Stephen V, Conkling, Paul, John, Thomas, Fakih, Marwan, Sigal, Darren, Loong, Herbert H, Buchschacher, Gary L, Garrido, Pilar, Nieva, Jorge, Steuer, Conor, Overbeck, Tobias R, Bowles, Daniel W, Fox, Elizabeth, Riehl, Todd, Chow-Maneval, Edna, Simmons, Brian, Cui, Na, Johnson, Ann, Eng, Susan, Wilson, Timothy R, Demetri, George D, and investigators, trial

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Trials and Supportive Activities, Clinical Research, 6.1 Pharmaceuticals, 5.1 Pharmaceuticals, Cancer, Good Health and Well Being, Aged, Antineoplastic Agents, Benzamides, Biomarkers, Tumor, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Female, Gene Fusion, Humans, Indazoles, Male, Membrane Glycoproteins, Middle Aged, Neoplasm Metastasis, Neoplasms, Protein Kinase Inhibitors, Receptor, trkA, Receptor, trkB, Receptor, trkC, Receptors, Nerve Growth Factor, Time Factors, Treatment Outcome, trial investigators, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundEntrectinib is a potent inhibitor of tropomyosin receptor kinase (TRK) A, B, and C, which has been shown to have anti-tumour activity against NTRK gene fusion-positive solid tumours, including CNS activity due to its ability to penetrate the blood-brain barrier. We present an integrated efficacy and safety analysis of patients with metastatic or locally advanced solid tumours harbouring oncogenic NTRK1, NTRK2, and NTRK3 gene fusions treated in three ongoing, early-phase trials.MethodsAn integrated database comprised the pivotal datasets of three, ongoing phase 1 or 2 clinical trials (ALKA-372-001, STARTRK-1, and STARTRK-2), which enrolled patients aged 18 years or older with metastatic or locally advanced NTRK fusion-positive solid tumours who received entrectinib orally at a dose of at least 600 mg once per day in a capsule. All patients had an Eastern Cooperative Oncology Group performance status of 0-2 and could have received previous anti-cancer therapy (except previous TRK inhibitors). The primary endpoints, the proportion of patients with an objective response and median duration of response, were evaluated by blinded independent central review in the efficacy-evaluable population (ie, patients with NTRK fusion-positive solid tumours who were TRK inhibitor-naive and had received at least one dose of entrectinib). Overall safety evaluable population included patients from STARTRK-1, STARTRK-2, ALKA-372-001, and STARTRK-NG (NCT02650401; treating young adult and paediatric patients [aged ≤21 years]), who received at least one dose of entrectinib, regardless of tumour type or gene rearrangement. NTRK fusion-positive safety evaluable population comprised all patients who have received at least one dose of entrectinib regardless of dose or follow-up. These ongoing studies are registered with ClinicalTrials.gov, NCT02097810 (STARTRK-1) and NCT02568267 (STARTRK-2), and EudraCT, 2012-000148-88 (ALKA-372-001).FindingsPatients were enrolled in ALKA-372-001 from Oct 26, 2012, to March 27, 2018; in STARTRK-1 from Aug 7, 2014, to May 10, 2018; and in STARTRK-2 from Nov 19, 2015 (enrolment is ongoing). At the data cutoff date for this analysis (May 31, 2018) the efficacy-evaluable population comprised 54 adults with advanced or metastatic NTRK fusion-positive solid tumours comprising ten different tumour types and 19 different histologies. Median follow-up was 12.9 months (IQR 8·77-18·76). 31 (57%; 95% CI 43·2-70·8) of 54 patients had an objective response, of which four (7%) were complete responses and 27 (50%) partial reponses. Median duration of response was 10 months (95% CI 7·1 to not estimable). The most common grade 3 or 4 treatment-related adverse events in both safety populations were increased weight (seven [10%] of 68 patients in the NTRK fusion-positive safety population and in 18 [5%] of 355 patients in the overall safety-evaluable population) and anaemia (8 [12%] and 16 [5%]). The most common serious treatment-related adverse events were nervous system disorders (three [4%] of 68 patients and ten [3%] of 355 patients). No treatment-related deaths occurred.InterpretationEntrectinib induced durable and clinically meaningful responses in patients with NTRK fusion-positive solid tumours, and was well tolerated with a manageable safety profile. These results show that entrectinib is a safe and active treatment option for patients with NTRK fusion-positive solid tumours. These data highlight the need to routinely test for NTRK fusions to broaden the therapeutic options available for patients with NTRK fusion-positive solid tumours.FundingIgnyta/F Hoffmann-La Roche.

Published
2020

12. Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group.

Author

Arvold, Nils D, Armstrong, Terri S, Warren, Katherine E, Chang, Susan M, DeAngelis, Lisa M, Blakeley, Jaishri, Chamberlain, Marc C, Dunbar, Erin, Loong, Herbert H, Macdonald, David R, Reardon, David A, Vogelbaum, Michael A, Yuan, Ying, Weller, Michael, van den Bent, Martin, and Wen, Patrick Y

Subjects
Clinical Trials and Supportive Activities, Pediatric, Brain Disorders, Clinical Research, Cancer, Neurosciences, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adrenal Cortex Hormones, Brain Edema, Brain Neoplasms, Humans, Neuroimaging, Risk Assessment, corticosteroids, endpoints, peritumor edema, RANO, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Background:Corticosteroids are the mainstay of treatment for peritumor edema but are often associated with significant side effects. Therapies that can reduce corticosteroid use would potentially be of significant benefit to patients. However, currently there are no standardized endpoints evaluating corticosteroid use in neuro-oncology clinical trials. Methods:The Response Assessment in Neuro-Oncology (RANO) Working Group has developed consensus recommendations for endpoints evaluating corticosteroid use in clinical trials in both adults and children with brain tumors. Results:Responders are defined as patients with a 50% reduction in total daily corticosteroid dose compared with baseline or reduction of the total daily dose to ≤2 mg of dexamethasone (or equivalent dose of other corticosteroid); baseline dose must be at least 4 mg of dexamethasone daily (or equivalent dose of other corticosteroids) for at least one week. Patients must have stable or improved Neurologic Assessment in Neuro-Oncology (NANO) score or Karnofsky performance status score or Eastern Cooperative Oncology Group (ECOG) (Lansky score for children age

Published
2018

13. Safety and anti-tumor activity of BAY 2927088 in patients with HER2-mutant NSCLC: Results from an expansion cohort of the SOHO-01 phase I/II study.

Author

Girard, Nicolas, primary, Kim, Tae Min, additional, Kim, Hye Ryun, additional, Loong, Herbert H., additional, Shinno, Yuki, additional, Lu, Shun, additional, Fang, Yong, additional, Zhao, Jun, additional, Nishino, Kazumi, additional, Lee, Ki Hyeong, additional, Miao, Liyun, additional, Sakamoto, Tomohiro, additional, Felip, Enriqueta, additional, Yang, Tsung-Ying, additional, Dooms, Christophe Alfons, additional, Tan, Daniel Shao-Weng, additional, Le, Xiuning, additional, Brase, Jan Christoph, additional, Grassi, Paolo, additional, and Goto, Koichi, additional

Published
2024
Full Text
View/download PDF

16. An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor–Refractory ALK-Positive or ROS1-Positive NSCLC

Author

Zhu, Viola W., Lin, Yen-Ting, Kim, Dong-Wan, Loong, Herbert H., Nagasaka, Misako, To, Hao, Ang, Yvonne Li-En, Ock, Chan-Young, Tchekmedyian, Nishan, Ou, Sai-Hong Ignatius, Syn, Nicholas L., Reungwetwattana, Thanyanan, Lin, Chia-Chi, and Soo, Ross A.

Published
2020
Full Text
View/download PDF

17. Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non–Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study

Author

Felip, Enriqueta, de Braud, Filippo G., Maur, Michela, Loong, Herbert H., Shaw, Alice Tsang, Vansteenkiste, Johan F., John, Thomas, Liu, Geoffrey, Lolkema, Martijn P., Selvaggi, Giovanni, Giannone, Vanessa, Cazorla, Pilar, Baum, Jason, Balbin, O. Alejandro, Wang, Luojun (Victor), Lau, Yvonne Y., Scott, Jeffrey W., and Tan, Daniel Shao-Weng

Published
2020
Full Text
View/download PDF

18. COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials

Author

Desai, Aakash, Gainor, Justin F., Hegde, Aparna, Schram, Alison M., Curigliano, Giuseppe, Pal, Sumanta, Liu, Stephen V., Halmos, Balazs, Groisberg, Roman, Grande, Enrique, Dragovich, Tomislav, Matrana, Marc, Agarwal, Neeraj, Chawla, Sant, Kato, Shumei, Morgan, Gilberto, Kasi, Pashtoon M., Solomon, Benjamin, Loong, Herbert H., Park, Haeseong, Choueiri, Toni K., Subbiah, Ishwaria M., Pemmaraju, Naveen, and Subbiah, Vivek

Published
2021
Full Text
View/download PDF

21. NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial

Author

Bonvalot, Sylvie, Rutkowski, Piotr L, Thariat, Juliette, Carrère, Sébastien, Ducassou, Anne, Sunyach, Marie-Pierre, Agoston, Peter, Hong, Angela, Mervoyer, Augustin, Rastrelli, Marco, Moreno, Victor, Li, Rubi K, Tiangco, Béatrice, Herraez, Antonio Casado, Gronchi, Alessandro, Mangel, László, Sy-Ortin, Teresa, Hohenberger, Peter, de Baère, Thierry, Le Cesne, Axel, Helfre, Sylvie, Saada-Bouzid, Esma, Borkowska, Aneta, Anghel, Rodica, Co, Ann, Gebhart, Michael, Kantor, Guy, Montero, Angel, Loong, Herbert H, Vergés, Ramona, Lapeire, Lore, Dema, Sorin, Kacso, Gabriel, Austen, Lyn, Moureau-Zabotto, Laurence, Servois, Vincent, Wardelmann, Eva, Terrier, Philippe, Lazar, Alexander J, Bovée, Judith V M G, Le Péchoux, Cécile, and Papai, Zsusanna

Published
2019
Full Text
View/download PDF

27. First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC

Author

Zhou, Caicun, primary, Solomon, Benjamin, additional, Loong, Herbert H., additional, Park, Keunchil, additional, Pérol, Maurice, additional, Arriola, Edurne, additional, Novello, Silvia, additional, Han, Baohui, additional, Zhou, Jianying, additional, Ardizzoni, Andrea, additional, Mak, M. Perez, additional, Santini, Fernando C., additional, Elamin, Yasir Y., additional, Drilon, Alexander, additional, Wolf, Jürgen, additional, Payakachat, Nalin, additional, Uh, Minji K., additional, Rajakumar, Deborah, additional, Han, Hongmei, additional, Puri, Tarun, additional, Soldatenkova, Victoria, additional, Lin, A. Bence, additional, Lin, Boris K., additional, and Goto, Koichi, additional

Published
2023
Full Text
View/download PDF

28. A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study)

Author

Ang, Yvonne L. E., primary, Zhao, Xiaotian, additional, Reungwetwattana, Thanyanan, additional, Cho, Byoung-Chul, additional, Liao, Bin-Chi, additional, Yeung, Rebecca, additional, Loong, Herbert H., additional, Kim, Dong-Wan, additional, Yang, James Chih-Hsin, additional, Lim, Sun Min, additional, Ahn, Myung-Ju, additional, Lee, Se-Hoon, additional, Suwatanapongched, Thitiporn, additional, Kongchauy, Kanchaporn, additional, Ou, Qiuxiang, additional, Yu, Ruoying, additional, Tai, Bee Choo, additional, Goh, Boon Cher, additional, Mok, Tony S. K., additional, and Soo, Ross A., additional

Published
2023
Full Text
View/download PDF

30. KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC).

Author

Cassier, Philippe Alexandre, primary, Dooms, Christophe Alfons, additional, Gazzah, Anas, additional, Felip, Enriqueta, additional, Steeghs, Neeltje, additional, Rohrberg, Kristoffer Staal, additional, De Braud, Filippo G., additional, Solomon, Benjamin J., additional, Schuler, Martin H., additional, Tan, Daniel Shao-Weng, additional, Yamamoto, Noboru, additional, Loong, Herbert H. F., additional, Cho, Byoung Chul, additional, Wolf, Juergen, additional, Lin, Chia-Chi, additional, Negrao, Marcelo Vailati, additional, Werner, Lillian, additional, Cui, Xiaoming, additional, Farago, Anna F., additional, and de Miguel, Maria J., additional

Published
2023
Full Text
View/download PDF

33. Abstract CT098: A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH, in advanced IDH-mutant cholangiocarcinoma and other solid tumors

Author

Rodon, Jordi, primary, Goyal, Lipika, additional, Mercade, Teresa Macarulla, additional, Ikeda, Masafumi, additional, Kondo, Shunsuke, additional, Oh, Do-Youn, additional, Bai, Li-Yuan, additional, Ueno, Makoto, additional, Italiano, Antoine, additional, Papadopoulos, Kyriakos, additional, Spigel, David, additional, Kizilbash, Sani H., additional, Cosman, Rasha, additional, Park, Joon Oh, additional, Chen, Li-Tzong, additional, Yokota, Tomoya, additional, Turk, Anita A., additional, Liao, Chih-Yi, additional, Shroff, Rachna, additional, El-Khoueiry, Anthony, additional, Satoh, Taroh, additional, Hollebecque, Antoine, additional, Borad, Mitesh J., additional, Azad, Nilofer, additional, Jaeckle, Kurt A., additional, Loong, Herbert H., additional, Adeva, Jorge, additional, Yong, Wei Peng, additional, Zhao, Junjie, additional, Liu, Hui, additional, Szpurka, Anna M., additional, Gueorguieva, Ivelina, additional, Pradhan, Kamnesh R., additional, Xu, Xiaojian, additional, and Harding, James J., additional

Published
2023
Full Text
View/download PDF

34. Supplementary Table S3 from Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

Author

Subbiah, Vivek, primary, Gainor, Justin F., primary, Oxnard, Geoffrey R., primary, Tan, Daniel S.W., primary, Owen, Dwight H., primary, Cho, Byoung Chul, primary, Loong, Herbert H., primary, McCoach, Caroline E., primary, Weiss, Jared, primary, Kim, Yu Jung, primary, Bazhenova, Lyudmila, primary, Park, Keunchil, primary, Daga, Haruko, primary, Besse, Benjamin, primary, Gautschi, Oliver, primary, Rolfo, Christian, primary, Zhu, Edward Y., primary, Kherani, Jennifer F., primary, Huang, Xin, primary, Kang, Suhyun, primary, and Drilon, Alexander, primary

Published
2023
Full Text
View/download PDF

35. Supplementary Data from Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

Author

Subbiah, Vivek, primary, Gainor, Justin F., primary, Oxnard, Geoffrey R., primary, Tan, Daniel S.W., primary, Owen, Dwight H., primary, Cho, Byoung Chul, primary, Loong, Herbert H., primary, McCoach, Caroline E., primary, Weiss, Jared, primary, Kim, Yu Jung, primary, Bazhenova, Lyudmila, primary, Park, Keunchil, primary, Daga, Haruko, primary, Besse, Benjamin, primary, Gautschi, Oliver, primary, Rolfo, Christian, primary, Zhu, Edward Y., primary, Kherani, Jennifer F., primary, Huang, Xin, primary, Kang, Suhyun, primary, and Drilon, Alexander, primary

Published
2023
Full Text
View/download PDF

36. Supplementary Figure S2 from Efficacy, Safety, and Pharmacokinetics of Axitinib in Nasopharyngeal Carcinoma: A Preclinical and Phase II Correlative Study

Author

Hui, Edwin P., primary, Ma, Brigette B. Y., primary, Loong, Herbert H. F., primary, Mo, Frankie, primary, Li, Leung, primary, King, Ann D., primary, Wang, Ki, primary, Ahuja, Anil T., primary, Chan, Charles M. L., primary, Hui, Connie W. C., primary, Wong, Chi H., primary, and Chan, Anthony T. C., primary

Published
2023
Full Text
View/download PDF

37. Supplementary Figure S1 from Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

Author

Subbiah, Vivek, primary, Gainor, Justin F., primary, Oxnard, Geoffrey R., primary, Tan, Daniel S.W., primary, Owen, Dwight H., primary, Cho, Byoung Chul, primary, Loong, Herbert H., primary, McCoach, Caroline E., primary, Weiss, Jared, primary, Kim, Yu Jung, primary, Bazhenova, Lyudmila, primary, Park, Keunchil, primary, Daga, Haruko, primary, Besse, Benjamin, primary, Gautschi, Oliver, primary, Rolfo, Christian, primary, Zhu, Edward Y., primary, Kherani, Jennifer F., primary, Huang, Xin, primary, Kang, Suhyun, primary, and Drilon, Alexander, primary

Published
2023
Full Text
View/download PDF

38. Author Correction: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials

Author

Desai, Aakash, Gainor, Justin F., Hegde, Aparna, Schram, Alison M., Curigliano, Giuseppe, Pal, Sumanta, Liu, Stephen V., Halmos, Balazs, Groisberg, Roman, Grande, Enrique, Dragovich, Tomislav, Matrana, Marc, Agarwal, Neeraj, Chawla, Sant, Kato, Shumei, Morgan, Gilberto, Kasi, Pashtoon M., Solomon, Benjamin, Loong, Herbert H., Park, Haeseong, Choueiri, Toni K., Subbiah, Ishwaria M., Pemmaraju, Naveen, and Subbiah, Vivek

Published
2021
Full Text
View/download PDF

39. Multinational Analysis of Estimated Health Care Costs Related to Extended-Interval Fixed Dosing of Checkpoint Inhibitors

Author

Goldstein, Daniel A., primary, Ginsberg, Gary M., additional, Hofnung-Gabbay, Dorit, additional, De Abreu Lourenco, Richard, additional, Loong, Herbert H., additional, Goh, Boon Cher, additional, Chan, Kelvin K. W., additional, Di Maio, Massimo, additional, Perrone, Francesco, additional, Hall, Peter S., additional, Zer, Alona, additional, and Rosenbaum, Eli, additional

Published
2023
Full Text
View/download PDF

42. Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong

Author

Loong, Herbert H., Wong, Carlos K. H., Leung, Linda Kam Suet, Dhankhar, Praveen, Insinga, Ralph P., Chandwani, Sheenu, Hsu, Danny C., Lee, Mary Y. K., Huang, Min, Pellissier, James, Rai, Akanksha, Achra, Monika, and Tan, Seng Chuen

Abstract

Background: Pembrolizumab, a monoclonal antibody against programmed death ligand 1 (PD-L1), is approved by several regulatory agencies for first-line treatment of metastatic non-small-cell lung cancer (NSCLC) with a PD-L1 tumor proportion score (TPS)?=?50% and no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase genomic tumor aberrations. This study was conducted from the perspective of the Hospital Authority in Hong Kong and aimed to evaluate the cost effectiveness of a biomarker (PD-L1) test-and-treat strategy (BTS), in which patients with a TPS?=?50% received pembrolizumab and other patients received platinum doublet chemotherapy versus all patients receiving platinum doublet chemotherapy. Methods: The model used a partitioned survival approach to estimate the incremental cost-effectiveness ratio (ICER) expressed as the cost per quality-adjusted life-year (QALY) gained. The clinical efficacy, utility and safety data were derived from the KN024 trial. Costs and health outcomes were projected over a 10-year time horizon and discounted at 3% per year. Costs for drug acquisition, PD-L1 testing, drug administration and disease management were used. Sensitivity analyses were conducted to evaluate the robustness of results. Results: The BTS approach led to an increase of 0.29 QALYs at an additional cost of Hong Kong dollars (HK$) 249,077 (US$31,933) compared with platinum doublet chemotherapy, resulting in an ICER of HK$865,189 (US$110,922) per QALY gained. This is lower than the World Health Organization cost-effectiveness threshold of three times the 2016 gross domestic product (GDP) per capita for Hong Kong of HK$1017,819 (US$130,490). Probabilistic sensitivity analyses showed a 59.4% chance that the ICER would be below this threshold. Conclusion: First-line treatment with pembrolizumab in a BTS to identify patients with NSCLC with PD-L1 TPS?=?50% can be considered cost effective in Hong Kong compared with platinum doublet chemotherapy based on a three-times GDP per capita threshold. However, local data on clinical efficacy and safety were not available to estimate overall survival (OS) and progression-free survival (PFS) specific to patients with NSCLC in Hong Kong. Further, uncertainty is inherent in the survival projections/extrapolation of PFS and OS beyond the trial period, and future research may help to further inform these parameters.

Published
2024
Full Text
View/download PDF

43. Final Safety and Health-Related Quality of LIfe Results of the Phase 2/3 Act.In.Sarc Study With Preoperative NBTXR3 Plus Radiation Therapy Versus Radiation Therapy in Locally Advanced Soft-Tissue Sarcoma

Author

Bonvalot, Sylvie, primary, Rutkowski, Piotr L., additional, Thariat, Juliette, additional, Carrère, Sébastien, additional, Ducassou, Anne, additional, Sunyach, Marie-Pierre, additional, Agoston, Peter, additional, Hong, Angela M., additional, Mervoyer, Augustin, additional, Rastrelli, Marco, additional, Moreno, Victor, additional, Li, Rubi K., additional, Tiangco, Béatrice J., additional, Casado Herráez, Antonio, additional, Gronchi, Alessandro, additional, Sy-Ortin, Teresa, additional, Hohenberger, Peter, additional, de Baère, Thierry, additional, Cesne, Axel Le, additional, Helfre, Sylvie, additional, Saada-Bouzid, Esma, additional, Anghel, Rodica M., additional, Kantor, Guy, additional, Montero, Angel, additional, Loong, Herbert H., additional, Vergés, Ramona, additional, Kacso, Gabriel, additional, Austen, Lyn, additional, Servois, Vincent F., additional, Wardelmann, Eva, additional, Dimitriu, Mikaela, additional, Said, Patricia, additional, Lazar, Alexander J., additional, Bovée, Judith V.M.G., additional, Le Péchoux, Cécile, additional, and Pápai, Zsusanna, additional

Published
2022
Full Text
View/download PDF

44. Patterns of care and survival of Chinese glioblastoma patients in the temozolomide era: a Hong Kong population-level analysis over a 14-year period

Author

Woo, Peter Y M, primary, Yau, Stephen, additional, Lam, Tai-Chung, additional, Pu, Jenny K S, additional, Li, Lai-Fung, additional, Lui, Louisa C Y, additional, Chan, Danny T M, additional, Loong, Herbert H F, additional, Lee, Michael W Y, additional, Yeung, Rebecca, additional, Kwok, Carol C H, additional, Au, Siu-Kie, additional, Tan, Tze-Ching, additional, Kan, Amanda N C, additional, Chan, Tony K T, additional, Mak, Calvin H K, additional, Mak, Henry K F, additional, Ho, Jason M K, additional, Cheung, Ka-Man, additional, Tse, Teresa P K, additional, Lau, Sarah S N, additional, Chow, Joyce S W, additional, El-Helali, Aya, additional, Ng, Ho-Keung, additional, and Poon, Wai-Sang, additional

Published
2022
Full Text
View/download PDF

47. Abstract CT033: KontRASt-01: A phase Ib/II, dose-escalation study of JDQ443 in patients (pts) with advanced, KRAS G12C-mutated solid tumors

Author

Tan, Daniel S., primary, Shimizu, Toshio, additional, Solomon, Benjamin, additional, Heist, Rebecca S., additional, Schuler, Martin, additional, Luken, Maria J. De Miguel, additional, Gazzah, Anas, additional, Wermke, Martin, additional, Dooms, Christophe, additional, Loong, Herbert H., additional, Steeghs, Neeltje, additional, Felip, Enriqueta, additional, Steuer, Conor E., additional, van Cutsem, Eric, additional, Soo, Ross A., additional, Jaeger, Ashley C., additional, Kim, Jaeyeon, additional, Xu, Kun, additional, Chen, Xueying, additional, Cui, Xiaoming, additional, Burks, Heather, additional, Farago, Anna, additional, and Cassier, Philippe A., additional

Published
2022
Full Text
View/download PDF

48. LIBRETTO-001 cohort 7: A single-arm, phase 2 study of neoadjuvant selpercatinib in patients with resectable stage IB-IIIA RET fusion-positive NSCLC.

Author

Rajaram, Ravi, primary, Sholl, Lynette M., additional, Dacic, Sanja, additional, Goldman, Jonathan W., additional, Tan, Daniel Shao-Weng, additional, Gautschi, Oliver, additional, Loong, Herbert H. F., additional, De Braud, Filippo G., additional, Massarelli, Erminia, additional, Levy, Benjamin Philip, additional, Dy, Grace K., additional, Kang, Suhyun, additional, Szymczak, Sylwia, additional, Chao, Bo H., additional, and Drilon, Alexander E., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results